课题基金 / 基金详情

PHARMACOKINETICS OF RIBAVIRIN IN SUBJECTS WITH CHRONIC LIVER DISEASE

PHARMACOKINETICS OF RIBAVIRIN IN SUBJECTS WITH CHRONIC LIVER DISEASE
利巴韦林在慢性肝病患者中的药代动力学
批准号：
6281007
负责人：
STEVEN SCHENKER
金额：
$1.49万
依托单位：
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-12-01 至 1998-11-30
来源：
https://reporter.nih.gov/project-details/6281007
关键词：
chronic disease /disorder clinical research clinical trial phase I combination chemotherapy dosage drug screening /evaluation hepatitis C human subject human therapy evaluation immunotherapy interferons liver disorder chemotherapy microorganism disease chemotherapy pharmacokinetics ribavirin

项目摘要

项目成果

STEVEN SCHENKER的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The treatment of chronic viral hepatitis with interferon is effective in only about 20% of such patients. Ribavirin can also lower abnormal liver tests in chronic hepatitis C. It is hoped that the combination of interferon and ribavirin therapy will improve the therapeutic potential of the individual drugs. This study will compare the elimination of a single dose of ribavirin in controls and patients with liver disease of varying severity thus permitting an assessment of the correct dose of ribavirin and of the drug combination in patients with chronic hepatitis C.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
FOOD RESTRICTION ON ACETAMINOPHEN METABOLISM & DISPOSITION
EFFECT OF POLYUNSATURATED LECITHIN ON LIVER FIBROSIS
FOOD RESTRICTION ON ACETAMINOPHEN METABOLISM & DISPOSITION
EFFECT OF POLYUNSATURATED LECITHIN ON LIVER FIBROSIS
海外基金